ORENCIA(R) (abatacept) Data Demonstrated Improvement In Children And Adolescents With Juvenile Idiopathic Arthritis
Tue, 14 Nov 2006 08:00 AM EST
... Bristol-Myers Squibb Company (NYSE: BMY) today announced results of the double-blind phase of an ongoing study, which show ORENCIA(R) (abatacept) demonstrated improvement in children with active juvenile idiopathic arthritis (JIA) who have had an inadequate response to one or more disease-mod [click link for full article] ...
Related Topics
- Juvenile Rheumatoid Arthritis
- Arthritis
- Rheumatoid Arthritis
- Data & Statistics
- Data Analysis
- National Data
- Gastroesophageal Reflux in Children and Adolescents
- Septic Arthritis
- Reactive Arthritis
- Mining
- Adolescents/Adolescence
- Juvenile Diabetes
- Clinical Laboratory Improvement Amendments
- Thrombocytopenia
- Juvenile primary lateral sclerosis
- Amyotrophic lateral sclerosis, type 2
- Adalimumab
- Logging
- Incarceration
- Chemical Safety

Not Signed In -


